BioCryst Pharma Analyst Ratings
BenzingaApr 10 07:08 ET
Buy Rating Affirmed for BioCryst Pharmaceuticals on Orladeyo's Success and Strong Growth Prospects
TipRanksFeb 26 11:25 ET
Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
BenzingaJan 8 05:52 ET
BioCryst Pharma Analyst Ratings
BenzingaJan 8 05:50 ET
JP Morgan Reinstates Overweight on BioCryst Pharma, Announces $10 Price Target
BenzingaNov 20, 2023 08:15 ET
BioCryst Pharma Analyst Ratings
BenzingaNov 20, 2023 08:14 ET
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
TipRanksNov 8, 2023 20:47 ET
BioCryst Pharmaceuticals' Promising Pipeline and Undervalued Stock: A Buy Rating Analysis
TipRanksNov 6, 2023 08:26 ET
BioCryst Pharma Analyst Ratings
BenzingaNov 6, 2023 06:32 ET
RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
BenzingaSep 25, 2023 12:01 ET
BioCryst Pharma Analyst Ratings
BenzingaSep 25, 2023 12:00 ET
RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10
BenzingaSep 18, 2023 07:16 ET
BioCryst Pharma Analyst Ratings
BenzingaSep 18, 2023 07:16 ET
RBC Capital Maintains Sector Perform on BioCryst Pharma, Raises Price Target to $9
BenzingaAug 4, 2023 10:36 ET
Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target
BenzingaAug 4, 2023 08:41 ET
HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target
BenzingaAug 4, 2023 06:14 ET
BioCryst Pharma Analyst Ratings
BenzingaAug 4, 2023 06:13 ET
Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12
BenzingaAug 3, 2023 13:27 ET
BioCryst Pharma Analyst Ratings
BenzingaAug 3, 2023 13:27 ET
BioCryst Pharma Analyst Ratings
BenzingaJul 13, 2023 06:21 ET
No Data
No Data